Publications by authors named "P Bulian"
The Bruton's tyrosine kinase (BTK) inhibitor ibrutinib represents an effective strategy for treatment of chronic lymphocytic leukemia (CLL), nevertheless about 30% of patients eventually undergo disease progression. Here we investigated by flow cytometry the long-term modulation of the CLL CXCR4/CD5 proliferative fraction (PF), its correlation with therapeutic outcome and emergence of ibrutinib resistance. By longitudinal tracking, the PF, initially suppressed by ibrutinib, reappeared upon early disease progression, without association with lymphocyte count or serum beta-2-microglobulin.
View Article and Find Full Text PDFArticle Synopsis
- In chronic lymphocytic leukemia (CLL), subclonal mutations below 10% to 15% variant allele frequency (VAF) have unclear clinical implications, but this study investigates their effect on patient survival and response to treatment.
- A comprehensive analysis of clinical features and mutation frequencies was conducted on two cohorts, with findings indicating that both high and low-VAF mutations were associated with significantly reduced overall survival compared to wild-type patients.
- The inclusion of low-VAF mutations provided better prognostic risk stratification in CLL than traditional models, suggesting a need to redefine what constitutes mutated CLL for improved clinical practice.